Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622675 | 0.86 | KCNJ6 (0.59) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL5142590 | 0.85 | MAPT (0.77) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL31236338 | 0.85 | MAPT (0.77) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL12526432 | 0.85 | MAPT (0.67) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL30977690 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL2184782 | 0.84 | SMN1; SMN2 (0.71) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL21580306 | 0.84 | HTT (0.76) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL9429509 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL30212894 | 0.83 | SMN1; SMN2 (0.69) | SMN1; SMN2MAPTMEN1KMT2AGAA | |
| SCHEMBL693942 | 0.83 | MAPT (0.72) | SMN1; SMN2MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508526-A1 | Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators | Ares Trading SA (CH) | 2012-10-10 | — | — | EP | disclosed |
| WO-2012130915-A1 | SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS | ARES TRADING S.A. (CH) | 2012-10-04 | — | — | WO | disclosed |
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1678168-B1 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-4944796-A | Certain 2-(disubstituted amino) acetanilide herbicides | ICI AMERICAS INC. (US) | 1990-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | SMN1; SMN2 2850/4885MAPT 3812/4885MEN1 4049/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | SMN1; SMN2 2850/4885MAPT 3812/4885MEN1 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.